Focusing on plasma glycoprotein VI.

摘要: New methods for analysing both platelet and plasma forms of the platelet-specific collagen receptor, glycoprotein VI (GPVI) in experimental models or human clinical samples, development first therapeutic compounds based on dimeric soluble GPVI-Fc anti-GPVI antibody-based constructs, coincide with increased understanding potential pathophysiological role GPVI ligand binding shedding. Platelet not only mediates activation at site vascular injury where is exposed, but also implicated pathogenesis other diseases, such as atherosclerosis coagulopathy, rheumatoid arthritis tumour metastasis. Here, we describe some critical mechanisms generating from platelets, future avenues exploiting this unique receptor diagnosis and/or disease prevention.